中国药物警戒 ›› 2025, Vol. 22 ›› Issue (9): 1049-1050.
DOI: 10.19803/j.1672-8629.20240764

• 安全与合理用药 • 上一篇    下一篇

苯扎贝特片致慢性肾病患者横纹肌溶解1例分析

李丹, 阳雄文, 陈丹君, 付成效, 阳波*   

  1. 南华大学附属第一医院药学部,湖南 衡阳 421001
  • 收稿日期:2024-09-30 发布日期:2025-09-22
  • 通讯作者: *阳波,男,本科,主任药师,药物临床评价。E-mail: ybnhfy@126.com
  • 作者简介:李丹,女,本科,主管药师,临床药学。
  • 基金资助:
    湖南省自然科学基金资助项目（2024JJ8149、2023JJ60494）

One Case of Rhabdomyolysis in Patients with Chronic Kidney Disease Caused by Benzafibrate Tablets

LI Dan, YANG Xiongwen, CHEN Danjun, FU Chengxiao, YANG Bo*   

  1. Department of Pharmacy, the First Affiliated Hospital, University of South China, Hengyang Hunan 421001, China
  • Received:2024-09-30 Published:2025-09-22

PDF (PC)

37

摘要： 目的 讨论慢性肾病患者中苯扎贝特相关性横纹肌溶解症的风险,为临床用药安全提供参考。方法 分析1例慢性肾病患者服用苯扎贝特片致横纹肌溶解病例,结合近5年文献系统分析该类患者病例特点及转归情况。结果 苯扎贝特可能是慢性肾病患者诱发横纹肌溶解症的危险因素,对症支持治疗后患者预后良好。结论 终末期肾病患者中,苯扎贝特致横纹肌溶解症的发生风险更高且其预后更严峻,临床应综合考虑其获益-风险,必要时可考虑监测血药浓度以及时有效地调整剂量。

关键词: 苯扎贝特片, 慢性肾病, 横纹肌溶解症, 药品不良反应

Abstract: Objective To analyze the risk of benzafibrate-associated rhabdomyolysis in patients with chronic kidney disease (CKD) so as to provide a reference for safe clinical use. Methods One case of CKD who developed rhabdomyolysis following bezafibrate administration was analyzed while related literature published over the past five years was reviewed to find out more about the clinical characteristics and outcomes in this population. Results Bezafibrate was possibly a risk factor for rhabdomyolysis in CKD patients, but the prognosis was good after symptomatic and supportive treatment. Conclusion Patients with end-stage renal disease are at higher risk of bdomyolysis caused by benzabate and the prognosis is undesirable. Serum drug concentrations have to be monitored and the dosage adjusted when needed.

Key words: Benzafibrate Tablets, Chronic Kidney Disease, Rhabdomyolysis, Adverse Drug Reactions

中图分类号: